<DOC>
	<DOC>NCT01137292</DOC>
	<brief_summary>Assessment of safety and efficacy of voriconazole in real-life setting in the treatment of high risk patients with invasive fungal infections. The study is conducted in Slovakia only.</brief_summary>
	<brief_title>Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Male or female patient of age 2 years or older. Highrisk patients with proven, probable or possible invasive fungal infection (IFI) according to the EORTC/MSG criteria. Patients indicated for secondary prophylaxis of invasive aspergillosis. Patients with known hypersensitivity to voriconazole or to any of the excipients. Patients with contraindicated concomitant medications according to the SmPC. Children less than 2 years of age. Pregnancy and lactation.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>observational study</keyword>
	<keyword>voriconazole</keyword>
	<keyword>high-risk patients</keyword>
</DOC>